Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Search Close Search
Page Menu

Trudy Morrison

UMassMed Faculty Page

Inventions:

Title: Incorporation/Packaging Viral/Tumor Antigens in Virus-like Particle. UMMS15-47; Patent Pending.

  • The invention relates to a vaccine for Eptein Barr Virus. The prophylactic is a recombinant virus-like particle (VLP) comprising a Newcastle disease virus (NDV) matrix (M) protein, a NDV nucleocapsid (NP) protein, and one or more tumor-associated EBV antigens that is capable of illiciting CD4+ and CD8+ T cell responses. 

Title: VIRUS-LIKE PARTICLES AS VACCINES FOR PARAMYXOVIRUS UMMS09-28; Patent 9,216,212

  •  This patented invention provides a low risk, highly effective paramyxovirus vaccine that is compatible with population-wide distribution marketing goals of low cost and high production rates. The disclosed vaccine contains a virus-like particle (VLP) comprising a) Newcastle disease virus matrix (M) protein, b) Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein transmembrane domain (TM) protein, c) Newcastle Disease Virus heamagglutinin-neuraminidase (HN) protein cytoplasmic domain (CT) protein, and d) Respiratory Syncytial Virus (RSV) ectodomain protein, wherein said transmembrane (TM) protein is flanked by said cytoplasmic domain (CT) protein and said ectodomain protein.

Title: RESPIRATORY SYNCTIAL VIRUS (RSV) SEQUENCES FOR PROTEIN EXPRESSION AND VACCINES. UMMS09-03; Patent 8,580,2709,168,294  

  • This invention discloses a sequence of efficient cleavage point of F protein, of the respiratory syncytial virus (RSV) that causes infection. The cDNA has an optimized codon of F protein, which may be useful for developing a more effective RSV vaccine.

 

Innovation TopicsBiologics, Infectious DiseaseVaccinesEpstein barr virus, Small Molecules, VirologyRespiratory syncytial virus (RSV)